IN201721047406A - - Google Patents

Info

Publication number
IN201721047406A
IN201721047406A IN201721047406A IN201721047406A IN201721047406A IN 201721047406 A IN201721047406 A IN 201721047406A IN 201721047406 A IN201721047406 A IN 201721047406A IN 201721047406 A IN201721047406 A IN 201721047406A IN 201721047406 A IN201721047406 A IN 201721047406A
Authority
IN
India
Application number
IN201721047406A
Other languages
English (en)
Inventor
Sagar Baburao PATIL
Cheriyan AJI
Sandeep Dhondibhau POTE
Anirudha Bhagirath Kute
Nikhil Prabhakar Malewar
Makarand Krishnakumar Avachat
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Priority to PCT/IB2018/060716 priority Critical patent/WO2019130277A1/en
Priority to IN201721047406A priority patent/IN201721047406A/en
Publication of IN201721047406A publication Critical patent/IN201721047406A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN201721047406A 2017-12-30 2018-12-29 IN201721047406A (enExample)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB2018/060716 WO2019130277A1 (en) 2017-12-30 2018-12-29 Pharmaceutical formulations of azilsartan medoxomil
IN201721047406A IN201721047406A (enExample) 2017-12-30 2018-12-29

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721047406A IN201721047406A (enExample) 2017-12-30 2018-12-29

Publications (1)

Publication Number Publication Date
IN201721047406A true IN201721047406A (enExample) 2020-06-19

Family

ID=65278423

Family Applications (1)

Application Number Title Priority Date Filing Date
IN201721047406A IN201721047406A (enExample) 2017-12-30 2018-12-29

Country Status (2)

Country Link
IN (1) IN201721047406A (enExample)
WO (1) WO2019130277A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123592A1 (en) * 2020-12-08 2022-06-16 Alkem Laboratories Ltd Stable pharmaceutical composition of azilsartan medoxomil or pharmaceutical acceptable salt and processes for preparing thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022182778A1 (en) * 2021-02-24 2022-09-01 Nostrum Pharmaceuticals, Llc Pharmaceutical packages and methods of reducing formation of n-nitrosodimethylamine
CN116687922A (zh) * 2023-07-27 2023-09-05 山东鲁宁药业有限公司 一种含阿齐沙坦的药物组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
WO2007097451A1 (ja) 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬パッケージ
CN102813635A (zh) 2006-08-10 2012-12-12 武田药品工业株式会社 药物组合物
EP2068812B9 (en) 2006-09-25 2012-08-08 Takeda Pharmaceutical Company Limited Medicinal package
TWI415634B (zh) 2007-03-28 2013-11-21 Takeda Pharmaceutical 固態醫藥組成物
CN103096878B (zh) * 2011-05-23 2015-06-17 江苏恒瑞医药股份有限公司 包含苯并咪唑衍生物的固体药物组合物
WO2014102628A1 (en) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Stable pharmaceutical composition comprising azilsartan medoxomil
US20160008328A1 (en) * 2014-07-11 2016-01-14 Cadila Healthcare Limited Stable Pharmaceutical Package Comprising Azilsartan Medoxomil
CN105456210A (zh) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 一种高生物利用度的阿齐沙坦组合物
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123592A1 (en) * 2020-12-08 2022-06-16 Alkem Laboratories Ltd Stable pharmaceutical composition of azilsartan medoxomil or pharmaceutical acceptable salt and processes for preparing thereof

Also Published As

Publication number Publication date
WO2019130277A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
BR122021000189A2 (enExample)
BR112019008823A2 (enExample)
BR112020006084A8 (enExample)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020006283B1 (pt) Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico
BR112020009729B1 (pt) Inibidores de acss2 e métodos de uso dos mesmos
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112019023976B1 (pt) Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde
BR112020003314B1 (pt) Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112019016885B1 (pt) Remodelagem de imagem integrada e codificação de vídeo
BR112020001354B1 (pt) Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel
BR112019027876B1 (pt) Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações
BR112019026818B1 (pt) Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador
BR112019026880B1 (pt) Método de comunicação, método para receber dados, e, dispositivo
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante
BR112019014127B1 (pt) Composição farmacêutica para tratamento de tumores
BR112019017156B1 (pt) Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador
BR102017026429B1 (pt) Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros
BR112020006250B1 (pt) Primeira estação base e método de controle de estado em uma primeira estação base